Featured Research

from universities, journals, and other organizations

New Treatment Strategy For The Prevention Of Recurrent Depression

Date:
November 15, 2006
Source:
Virginia Commonwealth University
Summary:
Some patients who experience recurrent depression may benefit from long-term maintenance treatment with anti-depressant medication, according to a new study led by a Virginia Commonwealth University researcher.

Some patients who experience recurrent depression may benefit from long-term maintenance treatment with anti-depressant medication, according to a new study led by a Virginia Commonwealth University researcher.

Major depressive disorder is a recurrent condition that can have a profound impact on an individual's quality of life. In the United States, approximately 17 percent of individuals will experience major depressive disorder during their lifetime.

Of those who experience one episode of major depression, more than 50 percent will have a recurrence. After two episodes, more than 70 percent of patients will have a recurrence, and after three episodes that figure jumps to 90 percent. Each episode poses a new risk that the depression may not respond to treatment, making prevention of recurrent depression an important focus of long-term treatment.

In the November issue of the Journal of Clinical Psychiatry, Susan G. Kornstein, M.D., a professor of psychiatry and obstetrics and gynecology in VCU's School of Medicine and lead author on the study, reported with her colleagues that maintenance treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI) approved for the treatment of depression, may reduce the risk of recurrent depression in patients with major depressive disorder.

Between 2000 and 2003, researchers evaluated approximately 200 participants at 28 centers in the United States who had responded positively to eight weeks of treatment with one of four different SSRIs: fluoxetine, sertraline, paroxetine or citalopram. This was followed by four months of treatment with escitalopram. These participants were then randomly assigned to fixed-dose treatment with 10 or 20 mg of escitalopram or placebo for one year.

"Patients who were switched to placebo showed a significantly higher rate of depression recurrence (65 percent), compared to those who stayed on escitalopram (27 percent)," said Kornstein. "This was true even though the patients showed a full resolution of their depression at the start of maintenance treatment." The medication was found to be safe and well tolerated throughout the study, she said.

"These findings indicate the importance of maintenance therapy for patients with recurrent major depressive disorder beyond four to six months of improvement, even if a patient's depressive symptoms appear to be resolved," she said.

This work was funded by Forest Research Institute.

Kornstein is also the executive director of VCU's Mood Disorders Institute and VCU's Institute for Women's Health, designated a National Center of Excellence by the U.S. Department of Health and Human Services. She collaborated on the study with Anjana Bose, Ph.D., Dayong Li, Ph.D., Khalil G. Saikali, Ph.D., and Chetan Gandhi, Ph.D., who are researchers with Forest Research Institute.


Story Source:

The above story is based on materials provided by Virginia Commonwealth University. Note: Materials may be edited for content and length.


Cite This Page:

Virginia Commonwealth University. "New Treatment Strategy For The Prevention Of Recurrent Depression." ScienceDaily. ScienceDaily, 15 November 2006. <www.sciencedaily.com/releases/2006/11/061106144928.htm>.
Virginia Commonwealth University. (2006, November 15). New Treatment Strategy For The Prevention Of Recurrent Depression. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/11/061106144928.htm
Virginia Commonwealth University. "New Treatment Strategy For The Prevention Of Recurrent Depression." ScienceDaily. www.sciencedaily.com/releases/2006/11/061106144928.htm (accessed July 23, 2014).

Share This




More Mind & Brain News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Do Obese Women Have 'Food Learning Impairment'?

Do Obese Women Have 'Food Learning Impairment'?

Newsy (July 18, 2014) Yale researchers tested 135 men and women, and it was only obese women who were deemed to have "impaired associative learning." Video provided by Newsy
Powered by NewsLook.com
Does Mixing Alcohol and Energy Drinks Boost Urge To Drink?

Does Mixing Alcohol and Energy Drinks Boost Urge To Drink?

Newsy (July 18, 2014) A new study suggests that mixing alcohol with energy drinks makes you want to keep the party going. Video provided by Newsy
Powered by NewsLook.com
Pot Cooking Class Teaches Responsible Eating

Pot Cooking Class Teaches Responsible Eating

AP (July 18, 2014) Following the nationwide trend of eased restrictions on marijuana use, pot edibles are growing in popularity. One Boston-area cooking class is teaching people how to eat pot responsibly. (July 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins